Hypertension in type 2 diabetes--targeting angiotensin.
Cardiovascular disease accounts for around 60% of deaths in people with type 2 diabetes mellitus, and diabetes is the leading cause of renal dysfunction and premature death in the UK. A key factor in these outcomes is that many people with type 2 diabetes also have raised blood pressure, which increases the likelihood of vascular complications. Lowering elevated blood pressure, using one or more antihypertensive drugs, reduces illness and mortality rates in such people. National guidelines advocate the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor antagonists in selected patients with type 2 diabetes. Here we review whether such treatment offers advantages over other antihypertensive drugs.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents